Related Experiment Videos
Cell hybridization, hybridomas, and human hybridomas
S Shirahata1, Y Katakura, K Teruya
1Laboratory of Cellular Regulation Technology, Graduate School of Genetic Resources Technology, Kyushu University, Fukuoka, Japan.
Methods in Cell Biology
|July 2, 1998
Summary
Cell hybridization techniques, including polyethylene glycol-mediated fusion, are crucial for creating hybridomas. Researchers developed novel human fusion partners and in vitro immunization methods to advance human monoclonal antibody production for medical applications.
Area of Science:
- Cytotechnology and Immunology
- Monoclonal Antibody Production
Background:
- Cell hybridization is a fundamental cytotechnology, initially using the hemagglutinating virus of Japan and now commonly employing polyethylene glycol (PEG) for cell fusion.
- The preparation of human-human hybridomas has been limited by the absence of suitable fusion partner cell lines with high efficiency and no immunoglobulin production.
- Ethical considerations restrict the use of B lymphocytes immunized with specific antigens for human hybridoma development.
Purpose of the Study:
- To explain the principles and practical protocols of cell hybridization methods, focusing on mouse hybridoma preparation using PEG.
- To address challenges in human hybridoma preparation by introducing novel human fusion partner cell lines and in vitro immunization techniques.
- To review the applications of human monoclonal antibodies in medicine, including enhanced and multifunctional antibody designs.
Main Methods:
- Detailed protocols for mouse hybridoma preparation using polyethylene glycol-mediated cell fusion.
- Establishment and utilization of human parent cell lines (NAT-30, HO-323, A4H12) with high fusion efficiencies for human hybridoma production.
- Development and application of in vitro immunization methods for exposing B lymphocytes to antigens.
- Electrofusion techniques for human-human hybridoma preparation.
Main Results:
- Successful development of NAT-30 and HO-323 cell lines, enabling the creation of hybridomas producing cancer-specific human monoclonal antibodies.
- Establishment of the A4H12 cell line, a non-immunoglobulin-producing human T lymphoma derivative, facilitating the efficient generation of IgG-producing human hybridomas.
- Demonstration of in vitro immunization techniques to overcome limitations in obtaining antigen-sensitized B lymphocytes.
Conclusions:
- Novel human fusion partner cell lines and in vitro immunization strategies significantly advance human-human hybridoma technology.
- These advancements facilitate the production of human monoclonal antibodies, particularly IgG-producing ones, for diverse medical applications.
- Future directions include the development of supranatural monoclonal antibodies with enhanced affinity, specificity, and multifunctionality.